• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

变异株特异性 IgA 可预防奥密克戎感染。

Variant-Specific IgA Protects Against Omicron Infection.

机构信息

A*STAR Infectious Diseases Labs, Agency for Science, Technology and Research, Singapore, Singapore.

Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore.

出版信息

J Infect Dis. 2024 Aug 16;230(2):e287-e291. doi: 10.1093/infdis/jiad525.

DOI:10.1093/infdis/jiad525
PMID:37996071
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11326848/
Abstract

BACKGROUND

The emergence of rapidly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, coupled with waning vaccine-induced immunity, has contributed to the rise of vaccine breakthrough infections. It is crucial to understand how vaccine-induced protection is mediated.

METHODS

We examined 2 prospective cohorts of mRNA vaccinated and boosted individuals during the Omicron wave of infection in Singapore.

RESULTS

We found that individuals who remain uninfected over the follow-up period had a higher variant-specific IgA, but not IgG, antibody response at 1 month after booster vaccination, compared with individuals who became infected.

CONCLUSIONS

We conclude that IgA may have a potential contributory role in protection against Omicron infection. Clinical Trials Registration . NCT05142319.

摘要

背景

快速进化的严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）变种的出现，加上疫苗诱导免疫的减弱，导致了疫苗突破性感染的增加。了解疫苗诱导的保护作用是如何介导的至关重要。

方法

我们在新加坡的奥密克戎感染浪潮期间，检查了 2 个接受 mRNA 疫苗接种和加强针的前瞻性队列。

结果

我们发现，与感染的个体相比，在随访期间未感染的个体在加强针接种后 1 个月时具有更高的针对变异株的 IgA，但 IgG 抗体反应较低。

结论

我们的结论是，IgA 可能在预防奥密克戎感染方面具有潜在的作用。临床试验注册. NCT05142319。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8498/11326848/fafdf233c332/jiad525f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8498/11326848/98eafa2eda5e/jiad525f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8498/11326848/fafdf233c332/jiad525f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8498/11326848/98eafa2eda5e/jiad525f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8498/11326848/fafdf233c332/jiad525f2.jpg

相似文献

1
Variant-Specific IgA Protects Against Omicron Infection.变异株特异性 IgA 可预防奥密克戎感染。
J Infect Dis. 2024 Aug 16;230(2):e287-e291. doi: 10.1093/infdis/jiad525.
2
Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough.中和抗体测试支持在SARS-CoV-2奥密克戎突破感染后对年轻人采取加强免疫策略。
Eur J Med Res. 2025 Jan 6;30(1):7. doi: 10.1186/s40001-024-02240-5.
3
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.多元化的体液免疫和加强疫苗的影响：初次或第二次加强针前后 SARS-CoV-2 抗体特征和奥密克戎 BA.2 的中和作用。
Microbiol Spectr. 2024 Oct 3;12(10):e0060524. doi: 10.1128/spectrum.00605-24. Epub 2024 Aug 20.
4
Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.BNT162b2 或 mRNA-1273 异源加强接种后 SARS-CoV-2 IgA、IgG、中和和总抗体反应的随访和比较评估。
Influenza Other Respir Viruses. 2024 May;18(5):e13290. doi: 10.1111/irv.13290.
5
Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.奥密克戎变异株在日本流行期间加强针接种后 SARS-CoV-2 抗体效价的动力学。
Vaccine. 2024 Aug 30;42(21):126156. doi: 10.1016/j.vaccine.2024.126156. Epub 2024 Jul 31.
6
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.首次感染 SARS-CoV-2 奥密克戎变异株可增强 mRNA 疫苗接种者的免疫效果：PRIBIVAC 随机临床试验第一阶段的最终结果。
EBioMedicine. 2024 Sep;107:105275. doi: 10.1016/j.ebiom.2024.105275. Epub 2024 Aug 12.
7
Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.新型冠状病毒肺炎疫苗接种计划启动后，免疫缺陷病（IEI）患者接种新型冠状病毒肺炎加强针的免疫原性及其一年临床随访
Front Immunol. 2024 Apr 18;15:1390022. doi: 10.3389/fimmu.2024.1390022. eCollection 2024.
8
Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.BNT162b2同源和科兴- BNT162b2异源加强疫苗接种中S1-RBD-IgG和S1-RBD-IgA的可比且持续水平：马来西亚一项为期22个月的前瞻性研究
Vaccine. 2024 Dec 2;42(26):126471. doi: 10.1016/j.vaccine.2024.126471. Epub 2024 Oct 28.
9
Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.奥密克戎变异株流行期间，癌症患者接种 COVID-19 疫苗后针对 SARS-CoV-2 刺突蛋白的免疫应答：一项前瞻性研究。
J Infect Public Health. 2024 Jul;17(7):102473. doi: 10.1016/j.jiph.2024.102473. Epub 2024 Jun 7.
10
Follow-up SARS-CoV-2 serological study of a health care worker cohort following COVID-19 booster vaccination.新冠病毒加强疫苗接种后医护人员队列的后续严重急性呼吸综合征冠状病毒2血清学研究
BMC Infect Dis. 2024 Apr 24;24(1):436. doi: 10.1186/s12879-024-09338-5.

本文引用的文献

1
Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population.体液免疫反应与接种疫苗的美国军人人群中对 SARS-CoV-2 突破感染的控制有关。
EBioMedicine. 2023 Aug;94:104683. doi: 10.1016/j.ebiom.2023.104683. Epub 2023 Jul 4.
2
Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant.异源mRNA疫苗加强针可诱导针对奥密克戎XBB变体产生更强且更持久的抗体反应。
Lancet Reg Health West Pac. 2023 Apr;33:100732. doi: 10.1016/j.lanwpc.2023.100732. Epub 2023 Mar 7.
3
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort.
SARS-CoV-2 抗体与 Virus Watch 队列中的突破性感染。
Nat Commun. 2022 Aug 18;13(1):4869. doi: 10.1038/s41467-022-32265-5.
4
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose.两剂 BNT162b2 疫苗接种后，老年人的疫苗获得性免疫下降，第三剂疫苗可缓解这种情况。
Nat Commun. 2022 Aug 8;13(1):4615. doi: 10.1038/s41467-022-32312-1.
5
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.异源与同源信使 RNA 疫苗加强针对严重急性呼吸综合征冠状病毒 2 型奥密克戎变异株的抗体反应：PRIBIVAC 研究的中期结果，一项随机临床试验。
Clin Infect Dis. 2022 Dec 19;75(12):2088-2096. doi: 10.1093/cid/ciac345.
6
Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection.接种 SARS-CoV-2 mRNA 疫苗后，机体可产生不同程度的系统性和黏膜性 IgA 应答，且与预防后续感染相关。
Mucosal Immunol. 2022 May;15(5):799-808. doi: 10.1038/s41385-022-00511-0. Epub 2022 Apr 25.
7
Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.尽管接种了mRNA疫苗加强针，但仍出现了新冠病毒奥密克戎变异株突破性感染。
Lancet. 2022 Feb 12;399(10325):625-626. doi: 10.1016/S0140-6736(22)00090-3. Epub 2022 Jan 18.
8
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.奥密克戎变异株对抗体介导的中和作用具有高度抗性：对控制 COVID-19 大流行的影响。
Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.
9
Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks.受体结合域-IgG 水平与面临 SARS-CoV-2 B.1.1.7 暴发的居民的保护相关。
Allergy. 2022 Jun;77(6):1885-1894. doi: 10.1111/all.15142. Epub 2021 Oct 29.
10
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.新冠疫苗突破性感染在已接种疫苗的医护人员中发生。
N Engl J Med. 2021 Oct 14;385(16):1474-1484. doi: 10.1056/NEJMoa2109072. Epub 2021 Jul 28.